| Code | CSB-RA932279MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to ozuriftamab, designed for research applications targeting receptor tyrosine kinase-like orphan receptor 2 (ROR2). ROR2 is a transmembrane receptor that plays critical roles in non-canonical Wnt signaling pathways, regulating cell polarity, migration, and skeletal development during embryogenesis. In adult tissues, aberrant ROR2 expression has been implicated in various malignancies, including renal cell carcinoma, melanoma, and osteosarcoma, where it contributes to tumor progression, metastasis, and therapeutic resistance. The receptor's involvement in cancer stem cell maintenance and epithelial-mesenchymal transition makes it an important target for oncology research.
Ozuriftamab is a therapeutic antibody candidate that has been developed to target ROR2-expressing tumors, with particular focus on renal cell carcinoma and other solid malignancies. This biosimilar antibody provides researchers with a valuable tool for investigating ROR2-mediated signaling mechanisms, evaluating potential therapeutic strategies, and studying the receptor's role in cancer biology and developmental processes.
There are currently no reviews for this product.